Skip to content

You are about to review presentations, reports, filings and/or other materials regarding Amarin Corporation plc (NASDAQ: AMRN) that contain time-sensitive information. The information contained therein is only current as of the date thereof and may not be a complete listing of all documents filed with the Securities Exchange Commission, made public or provided to Amarin shareholders.


Amarin expressly disclaims any obligation to review, update or correct these materials after the date thereof. Amarin may update, amend, supplement or otherwise alter the information contained in any such materials by subsequent presentations, reports, filings, or other means without notice.


Certain statements made on this web site or in materials accessed in or through the investor relations section of our web site are "forward-looking statements," which are subject to risks and uncertainties, and Amarin's actual results may differ (possibly materially) from those indicated in such statements. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q.


This website is not an offer or a solicitation to buy or sell securities. Please be aware that decisions regarding investments are the responsibility of users. Although this website includes information regarding pharmaceuticals (including products under development), the information is not intended as any advertisement and/or medical advice.


This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates.


Information on this website may be revised without any prior notice.

Investor Relations / Investor FAQs

Investor FAQs

Please click here for a fact sheet on VASCEPA and a glossary of related terms.

Show All
What is Amarin doing to protect the Vascepa® franchise against dietary supplement manufacturers that mislead the public by referencing REDUCE-IT™ or Vascepa®? (updated May 7, 2019)

Amarin is fully committed to defending the Vascepa® franchise against any company that seeks to mislead the public and cardiovascular patients in need by fraudulently leveraging the landmark REDUCE-IT study results or the REDUCE-IT or Vascepa® names for profit. Amarin is prepared to file multiple lawsuits should it become aware of any such claims.

For example, on October 29, 2018, Amarin filed two lawsuits in U.S. federal court, each against a different dietary supplement company for unlawfully using the results from Amarin’s landmark REDUCE-IT cardiovascular outcomes study of Vascepa® to falsely and deceptively claim that their omega-3 dietary supplement products are effective in reducing cardiovascular risk. The defendants in the cases were Omax Health, Inc. and The Coromega Company, Inc.

In April 2019, Omax and Coromega settled these litigations under terms by which Omax and Coromega agreed to substantially all the demands in Amarin’s complaints. Under the settlements, Coromega and Omax agreed to publicly correct their prior statements that wrongly suggested Amarin’s REDUCE-IT cardiovascular outcomes trial supports the safety and efficacy of omega-3 dietary supplements. Each dietary supplement company also acknowledged that as a general matter under federal law dietary supplements may be lawfully marketed to supplement the diet, but they cannot be lawfully marketed to treat, mitigate, or prevent disease, such as cardiovascular disease.

As the Coromega and Omax corrective statements make clear, the REDUCE-IT study is applicable only to Vascepa®, an FDA-approved drug comprised of icosapent ethyl, a single omega-3 acid, and was not designed to test the efficacy of any dietary supplement. The corrective statements also make clear that federal law prohibits dietary supplement companies, like Omax and Coromega, from claiming their dietary supplements treat, mitigate or prevent disease, such as cardiovascular disease, and from suggesting dietary supplements are substitutes for disease therapies, like Vascepa®. Additionally, and consistent with the corrective statements, the settlements bar Coromega and Omax from:

  • suggesting that the REDUCE-IT study (or any other Amarin study of Vascepa®) implies use of their omega-3 dietary supplement products would have similar results;
  • making any statements regarding the comparability, substitutability, or superiority of each company’s omega-3 products to Vascepa®; and
  • claiming that their omega-3 dietary supplements lower or reduce high triglycerides.

Vascepa® is materially different from these products:

  1. Vascepa® is proven to lower cardiovascular risk based on the REDUCE-IT cardiovascular outcomes study whereas three recent meta-analyses published in highly respected medical journals show that there is no scientific consensus that omega-3 dietary supplements have any beneficial effect on cardiovascular disease risks, or even cardiovascular health more generally 1;
  2. Vascepa® is an FDA-approved drug designated by FDA as a new chemical entity based on its unique molecular structure;
  3. The active ingredient in Vascepa® is icosapent ethyl and not a mixture of omega-3 acids;
  4. Because omega-3 fatty acids are highly prone to oxidation (i.e., spoilage), Vascepa® is manufactured, encapsulated and packaged through a stringent and complex FDA-regulated process designed to effectively eliminate impurities and isolate and protect the fragile single molecule active ingredient from degradation;
  5. Vascepa® was developed as a prescription-only drug to be administered in high dosages and has a demonstrated safety profile; and
  6. Vascepa® is promoted for use in populations for which it has been proven to be safe and effective (for example, adult patients with severe hypertriglyceridemia).

The foregoing information is qualified in its entirety by Amarin’s complaints and related documents, copies of the complaints are available here (Coromega) and here (Omax).

Settlement documents for Coromega are available: here, here and here .

Settlement documents for Omax are available: here, here, and here.

  • David S. Siscovick et. al, Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association, 135 Circulation e867–e884, Table 8 (2017), (“available evidence does not support the use of [omega-3] supplements in the general population who are not at high risk for [cardiovascular disease]”); see also Ethan M. Balk et. al, Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review vi, (Evidence Report/Technology Assessment, Number 223), (Aug. 2016), (last accessed Oct. 26, 2018) (concluding that omega-3 supplements do not affect “major adverse [cardiovascular] events, all-cause death, sudden cardiac death, coronary revascularization, atrial fibrillation, or [blood pressure]” in populations at risk for, or with cardiovascular disease, or in “general healthy populations”)
  • Asmaa S. Abdelhamid, et al., Omega-3 Fatty Acids for the Primary and Secondary Prevention of Cardiovascular Disease, COCHRANE DATABASE OF SYSTEMATIC REVIEWS (July 2018), (“There is evidence that taking omega-3 capsules does not reduce heart disease, stroke or death.”)
  • Theingi Aung, et al., Associations of Omega-3 Fatty Acid Supplement Use with Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77,917 Individuals, 3 JAMA Cardiology (Jan. 31, 2018), After reviewing 10 studies involving 77,917 patients, the authors stated that “[t]his meta-analysis demonstrated that omega-3 fatty acids had no significant association with fatal or nonfatal coronary heart disease or any major vascular events. It provides no support for current recommendations for the use of such supplements in people with a history of [CHD].” Id.
What is Amarin’s view on the reliability of third-party script reporting services?
Please click here.
Where can I find the New England Journal of Medicine (NEJM) publication of the primary results of the REDUCE-IT cardiovascular outcomes study?

The primary results of the REDUCE-IT cardiovascular outcomes study, which demonstrated that Vascepa significantly lowers the rate of occurrence of major adverse cardiovascular events in at-risk patients, was published and can be found at:


Other publications pertaining to Vascepa and the science supporting Vascepa are available at:

What is the type of physician communication which occurred at the American Heart Association’s 2018 scientific sessions?
The AHA scientific sessions included scientific presentations, such as the late breaking clinical trial results discussion of REDUCE-IT results as presented on Saturday, November 10, 2018, as well as various other academically focused discussions.  Examples of those other discussions are in the form of independently organized continuing medical education (CME) programs.  While the organizers of such CME programs do not make their entire presentations public, following is a link to the publicly available portion of the CME program that was organized by Medtelligence and made public via ReachMD:
Why has an outcomes study not been conducted for patients with TG levels ≥500 mg/dL?
Please click here
How does Vascepa work in lowering cardiovascular risk (Updated April 18, 2019)?
Please click here
What is the difference between using TG levels as an identifier of CV risk and correlating lowering TG levels and lowering CV risk?
Please click here.
What is the clinical need and scientific rationale for the REDUCE-IT study (Updated March 19, 2019)?

Please click here.

What is Amarin’s perspective on the use of mineral oil in its clinical trials and the variability commonly observed in blood-based lipid values in clinical trials of statin-stabilized patients (updated November 23, 2018)?

Please click here.

I heard the Global Principal Investigator for the REDUCE-IT study comment in his late-breaker presentation at AHA that there was no change in hsCRP in the placebo-arm of the study, please explain why that was referenced?

Please click here.

What is Amarin’s perspective on the editorial in NEJM commenting on the primary publication of REDUCE-IT results in NEJM (Bhatt et al. 2018)?
Please click here
What is Amarin’s opinion on the VITAL clinical trial?

Please click here.

What is Amarin’s opinion on the ASCEND clinical trial?

Please click here.

What is Amarin’s perspective regarding the complete response letter that Novartis received regarding its drug canakinumab as a potential treatment for cardiovascular risk reduction?

Please click here

Where can I find the approved label for Vascepa?
How can I keep up to date with latest developments at Amarin?

You can register to receive updates announced by Amarin by submitting your email address on the Mailing List section of our website, which option can be found on each page of the website Alternatively you can send an email to requesting to be notified of any new updates announced

What is Amarin's perspective on the results of Novartis' CANTOS study on canakinumab (Updated March 19, 2019)

Please see the attached document for a detailed response. This information is intended for communication with investors and should not be construed as marketing the use of any Amarin products or product candidates. Click Here.

What does Amarin think about the JAMA and Cochrane omega-3 meta-analyses?

Please click here.

Where can I get a copy of the August 2015 First Amendment opinion and March 2016 settlement resulting from the May 2015 lawsuit filed by Amarin and a group of independent physicians?
For opinion click here
For settlement click here 
What is the status of the ITC lawsuit Amarin filed in August 2017 to prevent the import and sale into the United States of synthetic omega-3 products that are comprised predominantly of EPA and sold for use in, or as, dietary supplements?
Please click here
What is Amarin’s policy on market rumors, speculation and related stock price movements?
Amarin has a general policy to not comment on rumors or speculation, or stock price movement related to such rumors or speculation. A “no comment” comment from Amarin is neither confirmation nor denial of any given rumor or speculation; it simply relays that Amarin has no comment on the matter.
Is Amarin subject to the UK City Code on Takeovers and Mergers?

Amarin Corporation plc is not subject to the UK City Code on Takeovers and Mergers (the “Code”) because the central management and control of Amarin is situated outside the UK. Amarin is therefore not subject to Code requirements, including but not limited to, press release requirements if, under certain circumstances, the company is “the subject of rumour or speculation” or there is an “untoward movement” in the target share price.

Amarin is subject to the UK Companies Act 2016 as a company organized under the law of England and Wales. For more information, please review the public disclosures in our most recent 10-K, page 67-68:

Despite being a company organized under such law, Amarin has an Irish, and not UK, tax residency for its parent company and for its wholly-owned subsidiary within which Vascepa revenues are recorded.

On what stock exchanges are Amarin's ordinary shares traded?

Amarin's ordinary shares, represented by American Depositary Shares, are listed on the NASDAQ Capital Market under the ticker AMRN.

Until July 16th 2008, Amarin's ordinary shares were also listed on London's AIM (ticker: AMRN) and Dublin's IEX (ticker: H2E).

What is an ADS/ADR?

    An American Depositary Share (ADS) is a security that represents an ownership interest in the shares of a foreign company trading on a U.S. securities market. The shares represented by the ADSs are held by a U.S. depositary bank and are evidenced by certificates called American Depositary Receipts (ADRs), although the terms ADS and ADR are often used interchangeably. ADRs enable U.S. investors to buy shares in foreign companies without undertaking cross-border transactions (i.e., in U.S. dollars), and they trade, clear and settle in accordance with U.S. market regulations and conventions.

What types of companies issue ADRs?

Non-U.S. companies whose securities trade on a U.S. securities market.

What is the ratio of Amarin ADRs to Amarin ordinary shares?

One Amarin ADR equals one Amarin ordinary share.

Are holders of ADRs entitled to vote at Amarin's annual general meeting?

Holders of ADRs may authorize Citibank, Amarin's Depositary, to act as a proxy in exercising voting rights according to the number of ordinary shares represented by their respective ADRs.

When is Amarin's fiscal year?

Amarin's fiscal year is the 12-month calendar year ending December 31st.

Where can I get information on the company?

Please visit our website at where you can read more on our executive team, board of directors, company strategy, corporate governance, therapeutic focus, product pipeline and partnering activities.

Where are Amarin's headquarters?

Amarin is headquartered in Dublin, Ireland.

Where can I find Amarin's financial statements?

Amarin's financial statements, including annual reports, can be found on Amarin's website in the Investor Relations section here. Alternatively, you can find all of Amarin's filings with the U.S. Securities and Exchange Commission under the SEC Filings section of the website here.

Who is Amarin's Registrar/Transfer Agent?

The U.S. Transfer Agent for Amarin's ADS holders is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
Tel: +1-877-248-4237d

The Registrar for Amarin's ordinary shares is:

Citi - Depositary Receipt Services
388 Greenwich Street
14th Floor
New York, NY 10013


PO Box 4630,
Aspect House,
Spencer Road,
Lancing, West Sussex,
BN99 6QQ, England
Telephone: +44 121 415 7047d

Who is Amarin's Depositary?

The Depositary for Amarin's ADRs is:

Citibank Shareholder Services
P.O. Box 43077
Providence, RI 02940-5000
Tel: +1-877-248-4237d Fax: +1-201-324-3284d

Who is Amarin's independent registered public accounting firm?

Ernst & Young LLP

99 Wood Avenue South

Iselin, NJ 08830

Who can I contact regarding Amarin investor and shareholder related queries?

Please contact: Elisabeth Schwartz
Telephone (U.S.): 908-719-1315d

© 2019, Amarin Corporation
Privacy policy  |  Disclaimer
Dublin Office
2 Pembroke House, Upper Pembroke
Street 28-32
Dublin 2, Ireland
US Investor Relations
Amarin Pharma Inc.
1430 Route 206
Bedminster, NJ 07921 USA
+1 908 719 1315
+1 908 719 3012

Amarin Corporation